← back to search

Xiao‐Yong Man

King University · US
Area of research
Immunology · Dermatology
Research interest
Research focused on Atopic dermatitis and Eczema Area and Severity Index, with related work in Acne, MAPK/ERK pathway, Placebo. Notable publications include 'VEGF induces proliferation of human hair follicle dermal papilla cells through VEGFR-2-mediated activation of ERK', 'Clinical practice Guidelines for 5-Aminolevulinic acid photodynamic therapy for acne vulgaris in China', and 'Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial'.
h-index
citations
312
works
14
NIH funding
primary concept
email

Recent publications

Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in moderate-to-severe plaque psoriasis: a phase Ib, randomized, double-blind, placebo-controlled study
British Journal of Dermatology 2025cited by 3position: lastdoi
Efficacy and Safety of Extending Dosing Interval of Stapokibart in Patients with Atopic Dermatitis
Dermatitis 2025cited by 2position: middledoi
Efficacy and Safety of GR1802 in Patients With Moderate‐to‐Severe Atopic Dermatitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Trial
Dermatologic Therapy 2025cited by 2position: middledoi
Long‐term efficacy and safety of stapokibart for moderate‐to‐severe atopic dermatitis: 52‐week results from a phase 3 trial
Allergy 2024cited by 23position: middledoi
Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial
BioDrugs 2024cited by 14position: middledoi
Expert Consensus on Big Data Collection of Skin and Appendage Disease Phenotypes in Chinese
Phenomics 2024cited by 7position: middledoi
Efficacy and safety of topical minocycline foam (FMX101 4%) in treatment of Chinese subjects with moderate‐to‐severe facial acne vulgaris: A phase 3, multi‐centre, randomized, double‐blind, vehicle‐controlled study
Journal of the European Academy of Dermatology and Venereology 2024cited by 5position: middledoi
52574 Safety and efficacy of selective TYK2/JAK1 inhibitor, TLL-018, in moderate-to-severe plaque psoriasis
Journal of the American Academy of Dermatology 2024cited by 1position: middledoi
Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial
Chinese Medical Journal 2023cited by 35position: middledoi
Expert Consensus on the Treat-to-Target Strategy for Psoriasis With Biological Agents in China (Simplified Edition) #
International Journal of Dermatology and Venereology 2023cited by 3position: middledoi
Clinical practice Guidelines for 5-Aminolevulinic acid photodynamic therapy for acne vulgaris in China
Photodiagnosis and Photodynamic Therapy 2022cited by 52position: middledoi
Mupirocin blocks imiquimod-induced psoriasis-like skin lesion by inhibiting epidermal isoleucyl-tRNA synthetase
Cell Communication and Signaling 2022cited by 12position: lastdoi
VEGF induces proliferation of human hair follicle dermal papilla cells through VEGFR-2-mediated activation of ERK
Experimental Cell Research 2012cited by 125position: middledoi
VEGF upregulates VEGF receptor-2 on human outer root sheath cells and stimulates proliferation through ERK pathway
Molecular Biology Reports 2012cited by 28position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jiaqi Chen · Zhejiang Chinese Medical University4 papers (2012–2025)Min Zheng · Sun Yat-sen University3 papers (2012–2024)Jianyun Lu · Dalian Medical University3 papers (2023–2024)Yan Zhao · Southwestern Medical Center3 papers (2023–2024)Yuling Shi · China National Offshore Oil Corporation (China)3 papers (2023–2025)Qingchun Diao · Beijing University of Chinese Medicine3 papers (2023–2024)Xiaohua Tao · Nanchang University3 papers (2023–2024)Qianjin Lu · Jiangsu University3 papers (2023–2024)Fuqiu Li · Jilin University3 papers (2023–2024)Liming Wu · Zhejiang University3 papers (2023–2024)Linfeng Li · Huanggang Normal University2 papers (2023–2024) · 2 papers (2024–2025)Yumei Li · Qingdao University2 papers (2023–2024)Chunming Li · Nanchang University2 papers (2012–2012)Ping Wang · Jiangsu University2 papers (2024–2025)Xiaohong Zhu · Jinan University2 papers (2023–2024)Yuzhen Li · Harbin Medical University2 papers (2023–2024) · 2 papers (2012–2012)Litao Zhang · Tianjin University of Traditional Chinese Medicine2 papers (2023–2024) · 2 papers (2012–2012)